The efficacy of mecillinam against clinical multidrug-resistant Escherichia coli in a murine urinary tract infection model.
Pivmecillinam, a pro-drug of mecillinam, has been used extensively in Scandinavia for the treatment of acute lower urinary tract infections (UTI) caused by Enterobacterales. It is still an attractive first-line drug for the empirical treatment of UTIs due to the low prevalence of resistance, favorable impact on the intestinal microbiota as a pro-drug, and good in vitro efficacy against extended-spectrum β-lactamase (ESBL-) or plasmid-mediated AmpC-producing Escherichia coli. However, the optimal dosing of pivmecillinam as well as the in vivo efficacy against UTI caused by multidrug-resistant (MDR) broad-spectrum β-lactamase-producing E. coli has not been carefully studied. In this study, we compared the efficacy of two mimicked human dosing regimens of pivmecillinam (200 mg and 400 mg TID) against clinical E. coli strains including ESBL- (CTX-M-14 and -15), plasmid-mediated AmpC- (CMY-4 and -6) and carbapenemase-producers (NDM-1 and VIM-29) in a murine UTI model. Both dosing regimens reduced the number of CFU/ml in urine for all strains including the mecillinam resistant strains. Combining the effect for all six strains showed no significant differences in effect between doses for all three fluids/organs, but for each dose there was a highly significant effect in urine, kidney and bladder as compared to vehicle treated mice. Overall this highlights the need for further studies to elucidate the role of mecillinam in treatment of infections caused by MDR E. coli producing broad-spectrum β-lactamases including specific carbapenemases.